Výsledky vyhledávání - "Yukihiro, Okutani"

Medication-taking behavior in hypertensive patients with a single-tablet, fixed-dose combination in Japan

Autor: Yuko Tanaka, Kei Sagawa, Ikuo Saito, Yukihiro Okutani, Toshio Kushiro, Yasuyuki Matsushita, Yuki Sato, Masatoshi Tanigawa

Publikováno v: Clinical and Experimental Hypertension. 38:131-136

Non-persistence rate (defined as not remaining on treatment) in patients taking a renin angiotensin system inhibitor plus calcium channel blocker was studied in three integrated 12-weeks surveys by matching separate drug combination therapy (CT) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1208c6a3da149332c8c8b066d23f9c20
https://doi.org/10.3109/10641963.2015.1047949

Zobrazit plný text záznamu

[Study on the safety and efficacy of sitafloxacin at a dose of 100 mg once a day--results of the use-results survey]

Autor: Seiji, Hori, Kazuhiro, Uchino, Takuyuki, Matsumoto, Hiroki, Yamaguchi, Megumi, Takahashi, Satoko, Hamajima, Kaori, Nukui, Hisano, Eda, Akiko, Shiina, Atsushi, Takita, Naoki, Yamanouchi, Masami, Mizuno, Yukihiro, Okutani

Publikováno v: The Japanese journal of antibiotics. 67(3)

Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), an oral quinolone antibacterial agent, was approved additionally for administration at a dose of 100 mg once a day in August 2011. A use-results survey on STFX 100 mg/day was performed from Dece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::02127b721598461bfc2481e58ef4699e
https://pubmed.ncbi.nlm.nih.gov/25163251

Zobrazit plný text záznamu

[In vitro activity of sitafloxacin against clinical isolates in 2012]

Autor: Ayako, Amano, Kaoru, Matsuzaki, Naoko, Kishi, Hideaki, Koyama, Miyuki, Hasegawa, Fumiaki, Ikeda, Takuyuki, Matsumoto, Hiroki, Yamaguchi, Yukihiro, Okutani

Publikováno v: The Japanese journal of antibiotics. 66(6)

In vitro activity of sitafloxacin (STFX) and various oral antimicrobial agents against bacterial isolates recovered from clinical specimens between January and December 2012, at different healthcare facilities in Japan was evaluated. A total of 1,620

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b00421fb2ed4cb81168b5311872f786
https://pubmed.ncbi.nlm.nih.gov/24649797

Zobrazit plný text záznamu

[Efficacy and safety of sitafloxacin in patients with urinary tract infections]

Autor: Takuyuki, Matsumoto, Hiroki, Yamaguchi, Kazuhiro, Uchino, Megumi, Takahashi, Hiroko, Kodama, Satoko, Hamajima, Rie, Yonemochi, Sachiko, Fujita, Atsushi, Takita, Naoki, Yamanouchi, Tomoo, Shiozawa, Yukihiro, Okutani

Publikováno v: The Japanese journal of antibiotics. 65(6)

Sitafloxacin (STFX, Gracevit 50mg, fine granules 10%), a new quinolone antibacterial agent, was approved in January 2008, and the use-results survey was carried out over the 2 years between December 2008 and November 2010. We studied the efficacy and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1eea765dbdd633a27987668182f9aa0f
https://pubmed.ncbi.nlm.nih.gov/23593733

Zobrazit plný text záznamu

Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study

Autor: Yukihiro Okutani, Atsushi Hikita, Masanori Kawai, Mitsuru Suwa, Yoshihiro Mori, Nobushige Kurobe, Fumihiro Nomura

Publikováno v: Circulation journal : official journal of the Japanese Circulation Society. 72(11)

Background Recently, vasodilators have been increasingly being recognized as useful for the treatment of acute heart failure syndromes (AHFS). Although carperitide (α-human atrial natriuretic peptide) has vasodilatory, diuretic and organ-protective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50553fb49134f9e945a4d8117edfa651
https://pubmed.ncbi.nlm.nih.gov/18832779

Zobrazit plný text záznamu

Evaluation of UGT1A1 genotyping for predicting individual toxicity of irinotecan plus platinum analog regimens: Interim safety analysis of a prospective observational study

Autor: Takeshi Ikeda, Masashi Takano, Kaichiro Yamamoto, Yuji Minegishi, Kouzo Yamada, Takuma Yokoyama, Yuichi Ando, Satoshi Morita, Eiji Hirata, Junzo Kigawa, Yuh Sakata, Yasuo Ohashi, Yukihiro Okutani, Masahiro Sugihara, Toru Sugiyama, Tsutomu Tabata

Publikováno v: Journal of Clinical Oncology. 31:11049-11049

11049 Background: Irinotecan (IRI)+platinum (Pt) therapy works synergistically and is widely used for solid carcinomas. Although UGT1A1 genotyping has been implemented in daily practice since long, recommended doses of IRI+Pt therapy according to UGT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8727121e68270049cc4ad3361ebab957
https://doi.org/10.1200/jco.2013.31.15_suppl.11049

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání